Physician profile
Thomas Shaheen
NPI 1073503876
$2,137.43
in general payments reported to CMS, 2019-2025
22 companies · $198 in 2025
The $198 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $89.68 · 2021: $455 · 2022: $299 · 2023: $256 · 2024: $367 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $820.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $297.85 | 2021-2025 | Tryptyr, Clareon, Precision7 |
| Novartis Pharmaceuticals Corporation | $278.93 | 2019-2022 | |
| Coopervision INC. | $217.81 | 2022-2023 | Misight Contact Lens |
| Eyevance Pharmaceuticals LLC | $147.16 | 2021 | |
| Amgen INC. | $143.98 | 2024-2025 | Tepezza |
| Bausch & Lomb Americas INC. | $141.72 | 2024 | Infuse, Miebo |
| Aerie Pharmaceuticals, INC. | $133.54 | 2019 | |
| Shire North American Group INC | $101.60 | 2019 | |
| Oyster Point Pharma, INC. | $95.02 | 2022-2023 | Tyrvaya |
| Carl Zeiss Meditec, INC. | $83.52 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $68.89 | 2023 | Acuvue |
| Allergan, INC. | $68.49 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $66.08 | 2019-2022 | |
| Abb Con-Cise Optical Group LLC | $62.96 | 2019-2021 | |
| Harrow Eye, LLC | $49.11 | 2024-2025 | Vevye |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $41.89 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $33.71 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $29.25 | 2019-2021 | |
| Abbvie INC. | $27.43 | 2022-2025 | |
| Thea Pharma INC. | $17.14 | 2024 | Iyuzeh |
| Johnson & Johnson Surgical Vision, INC. | $15.98 | 2024 | Tecnis Iol |
| Dompe US, INC. | $15.37 | 2025 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Shaheen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.